US remote healthcare specialist ChronWell has raised $6 million from investors that will be used to accelerate the rollout of its patient management programmes for people with liver and gas
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh